First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

1. Paz-Ares, L.G.
2. Ciuleanu, T.-E.
3. Cobo, M.
4. Bennouna, J.
5. Schenker, M.
6. Cheng, Y.
7. Juan-Vidal, O.
8. Mizutani, H.
9. Lingua, A.
10. Reyes-Cosmelli, F.
11. Reinmuth, N.
12. Menezes, J.
13. Jassem, J.
14. Protsenko, S.
15. Richardet, E.
16. Felip, E.
17. Feeney, K.
18. Zurawski, B.
19. Alexandru, A.
20. de la Mora Jimenez, E.
21. Dakhil, S.
22. Lu, S.
23. Reck, M.
24. John, T.
25. Hu, N.
26. Zhang, X.
27. Sylvester, J.
28. Eccles, L.J.
29. Grootendorst, D.J.
30. Balli, D.
31. Neely, J.
32. Carbone, D.P.
33. Montrer des auteurs +